CHD/Prevention News

CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.

CHICAGO — People living in historically redlined neighborhoods with poor access to healthy foods were more likely to have type 2 diabetes, hypertension, coronary heart disease and obesity, researchers reported.

CHICAGO — Emailed messages emphasizing the CV benefits of influenza vaccination improved vaccine uptake among older and younger adults in Denmark, particularly among more vulnerable patients with a history of acute MI, researchers reported.

CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial.

CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial.

CHICAGO — For adults at high or very high CVD risk, a monthly PCSK9 inhibitor added to maximally tolerated oral lipid-lowering therapy maintained LDL reductions of more than 60% through 72 weeks, with no signals of attenuation.

CHICAGO — The rate of deaths from CVD increased in rural areas and decreased in urban areas of the U.S. from 2010 to 2022, and the difference was especially pronounced amid the COVID-19 pandemic and among younger adults, researchers reported.

Children with normal blood pressure may not need BP screenings as often as current recommendations call for, according to a longitudinal study published in JAMA Pediatrics.

Most lipid-lowering medications lack safety data for pregnant and lactating women, complicating management of hyperlipidemia and hypertriglyceridemia, but data suggest statins can be used for those at high risk for cardiovascular events.